The more we think about Johnson and Johnson (NYSE: JNJ) decision to shut down Animas the more it hits us just how much the insulin pump is about to change. As we noted earlier today Animas was no fly by night company they were the number 2 player in the insulin pump market with over 120,000 patients. They had, until recently, the backing of JNJ and still could not compete.
Now we know some are going to blame Medtronic (NYSE: MDT) for this so let’s put an end to that, Medtronic did not run Animas into the ground . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.